Nuvectis Pretax Profit Margin from 2010 to 2024
| NVCT Stock | USD 4.95 0.14 2.91% |
Pretax Profit Margin | First Reported 2010-12-31 | Previous Quarter (115.28) | Current Value (121.04) | Quarterly Volatility 3.65873953 |
Check Nuvectis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvectis Pharma's main balance sheet or income statement drivers, such as Interest Expense of 179.9 K, Selling General Administrative of 4.6 M or Selling And Marketing Expenses of 13.2 K, as well as many indicators such as Price To Sales Ratio of 510, Dividend Yield of 0.0 or PTB Ratio of 11.17. Nuvectis financial statements analysis is a perfect complement when working with Nuvectis Pharma Valuation or Volatility modules.
Nuvectis | Pretax Profit Margin |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.